Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 4/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD5 | P21918 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20540212 | 0.97 | DRD1 (0.42) | DRD1PDCD1CD274DRD2DRD4 | |
| SCHEMBL21507018 | 0.88 | DRD1 (0.40) | DRD1PDCD1CD274DRD2DRD4 | |
| SCHEMBL30498620 | 0.82 | DRD1 (0.49) | DRD1PDCD1CD274DRD2DRD4 | |
| SCHEMBL20294451 | 0.82 | DRD1 (0.49) | DRD1PDCD1CD274DRD2DRD4 | |
| SCHEMBL23783646 | 0.80 | ALDH1A1 (0.47) | ALDH1A1ALDH1A3BRD4MAPK1ELANE | |
| SCHEMBL28602844 | 0.79 | DRD1 (0.42) | DRD1PDCD1CD274DRD2DRD4 | |
| SCHEMBL30704990 | 0.79 | DRD1 (0.42) | DRD1PDCD1CD274DRD2DRD4 | |
| SCHEMBL5964342 | 0.79 | CYP2A6 (0.45) | DRD1PDCD1CD274DRD2DRD4 | |
| SCHEMBL8176332 | 0.78 | ALDH1A1 (0.58) | DRD1DRD2DRD4DRD5DRD3 | |
| SCHEMBL23783663 | 0.76 | ALDH1A1 (0.40) | CYP2A6ALDH1A1ALDH1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4688777-A1 | NOVEL PD-L1 INHIBITORS | Affirma Biotech S. L. (ES) | 2026-02-11 | — | — | EP | disclosed |
| EP-4600247-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-3781556-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024200308-A1 | NOVEL PD-L1 INHIBITORS | Affirma Biotech S. L. (ES) | 2024-10-03 | — | — | WO | disclosed |
| EP-4434987-A1 | NOVEL PD-L1 INHIBITORS | Affirma Biotech S. L. (ES) | 2024-09-25 | — | — | EP | disclosed |
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-3612525-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2021-10-27 | — | — | EP | disclosed |
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
| US-10899735-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-20190345131-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-11-14 | — | — | US | disclosed |
| WO-2019204609-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2018-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | DRD1 3853/4885PDCD1 2/4885CD274 1/4885 |
| US-10899735-B2 | PD-1/PD-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | DRD1 4247/4885PDCD1 1/4885CD274 2/4885 |
| US-20190345131-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | DRD1 4247/4885PDCD1 1/4885CD274 2/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | DRD1 989/4885PDCD1 3/4885CD274 1/4885 |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | DRD1 3853/4885PDCD1 2/4885CD274 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.